Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levulan PDT (Blue vs Red Light) for BCC in BCNS
NCT02157623Completed
- Start
- Feb 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of 5-aminolevulinic acid in basal cell carcinoma (BCC). Primary endpoint: Tumor Clearance Rate Following Red or Blue Light PDT at 6 months. Started Feb 2016; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT02157623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02157623.